Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.48−0.05 (-0.66%)
Close on Nov 18, 2026Market cap $3.39BP/E –Yield –
Iovance Biotherapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Iovance Biotherapeutics's price to sales ratio was 11.3× on Nov 11, 2026, against 3.8× a year earlier. Over the last 2 years it ranged from 2.7× to 105.8×, with a median of 6.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 11.3× | +7.1 |
| 2025 | Dec 31, 2025 | 4.2× | −20.6 |
| 2024 | Dec 31, 2024 | 24.8× | – |
See a number that looks wrong?